4-(diethylamino)benzaldehyde and ER-Negative PR-Negative HER2-Negative Breast Cancer

4-(diethylamino)benzaldehyde has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hara, Y; Koyanagi, S; Matsunaga, N; Ogino, T; Ohdo, S; Tanaka, T	1

Other Studies

1 other study(ies) available for 4-(diethylamino)benzaldehyde and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Optimized Dosing Schedule Based on Circadian Dynamics of Mouse Breast Cancer Stem Cells Improves the Antitumor Effects of Aldehyde Dehydrogenase Inhibitor. Cancer research, 2018, 07-01, Volume: 78, Issue:13 Topics: Aldehyde Dehydrogenase; Animals; Benzaldehydes; Cell Line, Tumor; Circadian Clocks; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Nerve Tissue Proteins; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Microenvironment; Wnt Proteins	2018

Article

Year

Optimized Dosing Schedule Based on Circadian Dynamics of Mouse Breast Cancer Stem Cells Improves the Antitumor Effects of Aldehyde Dehydrogenase Inhibitor.

Cancer research, 2018, 07-01, Volume: 78, Issue:13

Topics: Aldehyde Dehydrogenase; Animals; Benzaldehydes; Cell Line, Tumor; Circadian Clocks; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Nerve Tissue Proteins; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Microenvironment; Wnt Proteins

2018